| #49 |
Manuel Martinez-Sanchez |
MIT |
2 |
| #49 |
Matthew C. Lucas |
Hoffmann-La Roche |
2 |
| #49 |
Joel D. Moore |
Enanta Pharmaceuticals |
2 |
| #49 |
Ali M. Fakharzadeh |
— |
2 |
| #49 |
Robert D'Amato |
Children'S Medical Center |
2 |
| #49 |
Kripa K. Varanasi |
MIT |
2 |
| #49 |
Antonio Sanchez-Rubio |
MIT |
2 |
| #49 |
Hjalmar Edzer Ayco Huitema |
Creator Technology B.V. |
2 |
| #49 |
Martin Rommel |
American Science And Engineering |
2 |
| #49 |
Todd Carter |
Braincells |
2 |
| #49 |
David Lipschutz |
— |
2 |
| #49 |
Shelia M. Violette |
Biogen Idec Ma |
2 |
| #49 |
Bakul Khanna |
Avaya |
2 |
| #49 |
Srinivasa R. Cheruku |
Epix Delaware |
2 |
| #49 |
Karen Ruben |
Juniper Networks |
2 |
| #49 |
Susanne Hupfer |
IBM |
2 |
| #49 |
Shuang-Yong Xu |
New England Biolabs |
2 |
| #49 |
Susan Gail Schiffer |
Biogen Idec Ma |
2 |
| #49 |
Dmitry Fomitchev |
Cabot |
2 |
| #49 |
Jonah Samuel Myerberg |
Desktop Metal |
2 |
| #49 |
Hamed Eshraghian |
Avid Technology |
2 |
| #49 |
Jene A. Golovchenko |
Harvard University |
2 |
| #49 |
Paul M. Bober |
Emc |
2 |
| #49 |
Renu Chipalkatti |
Verizon |
2 |
| #49 |
Eran Orgad |
Emc |
2 |
| #49 |
Chet Birger |
Bladelogic |
2 |
| #49 |
Robert Yongxin Zhao |
Immunogen |
2 |
| #49 |
Noubar B. Afeyan |
Rubius Therapeutics |
2 |
| #49 |
Brian D. Schultz |
RTX (Raytheon) |
2 |
| #49 |
David P. Rounbehler |
Thermedics |
2 |
| #49 |
Subhakar Dey |
Dh Technologies Development Pte. |
2 |
| #49 |
Michael Roesler |
BMW |
2 |
| #49 |
Ron Ben-Natan |
IBM |
2 |
| #49 |
Robert D. Eckert |
Konarka Technologies |
2 |
| #49 |
Qizhi Liu |
IBM |
2 |
| #49 |
Chau-Chyun Chen |
Aspen Technology |
2 |
| #49 |
Dzevat Omeragic |
Schlumberger Technology |
2 |
| #49 |
Xiaoxiong Mo |
Arichell Technologies |
2 |
| #49 |
Randy S. Bethiel |
Vertex Pharmaceuticals Incorporated |
2 |
| #49 |
Weiwen Ying |
Synta Pharmaceuticals |
2 |
| #49 |
Dennis John Underwood |
Agenus |
2 |
| #49 |
Gary Zakon |
IBM |
2 |
| #49 |
Bruce A. Morgan |
The General Hospital |
2 |
| #49 |
Mark E. Kuznetsov |
Axsun Technologies |
2 |
| #49 |
Pui Yee Ng |
Forma Therapeutics |
2 |
| #49 |
Chia-Chih Ou |
W.R. Grace & Co.-Conn. |
2 |
| #49 |
Paul Schimmel |
Scripps Research |
2 |
| #49 |
Rui-Yang Yang |
Arqule |
2 |
| #49 |
Thomas Andrew Wynn |
Alkermes Pharma Ireland Limited |
2 |
| #49 |
Angela M. Belcher |
MIT |
2 |